ZYTIGA 250 MG — DIN 02371065
ABIRATERONE ACETATE : 250 MG · JANSSEN INC · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is ZYTIGA?
ZYTIGA 250 MG contains ABIRATERONE ACETATE : 250 MG. It is listed in the Health Canada Drug Product Database under DIN 02371065, held by JANSSEN INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 28-Jul-2011. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ZYTIGA used for?
Treatment of metastatic castration-resistant prostate cancer (mCRPC) and newly diagnosed hormone-sensitive high-risk metastatic prostate cancer, in combination with prednisone and/or ADT.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Abiraterone cost around the world?
Abiraterone is listed on 7 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Greece publishes a producer price (ex-factory); Hungary publishes a producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| United States | acquisition | 2 | 35 | USD███.██ |
| Greece | producer price (ex-factory) | 17 | 17 | EUR███.██ |
| Italy | ex-factory (classe H) | 9 | 17 | EUR███.██ |
| Australia | ex-manufacturer | 8 | 16 | AUD███.██ |
| Hungary | producer price (ex-factory) | 15 | 15 | HUF███.██ |
| United Kingdom | hospital | 2 | 2 | GBP███.██ |
| South Africa | single exit price | 1 | 1 | ZAR███.██ |
103 pack listings across 54 brand entries and 6 price bases, refreshed 08 Sep 2026. Ranges span every Abiraterone pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Abiraterone in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
10 holders have a Canadian DIN containing Abiraterone, across 24 DINs, of which 17 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| APOTEX INC | 4 | 2 | APO-ABIRATERONE, APO-ABIRATERONE ACETATE FILM COATED TABLETS, APO-ABIRATERONE FILM COATED TABLETS | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 4 | 2 | ABIRATERONE, JAMP ABIRATERONE | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 3 | 2 | SANDOZ ABIRATERONE | Sourceable in Canada |
| DR REDDY'S LABORATORIES LTD | 2 | 2 | REDDY-ABIRATERONE | Sourceable in Canada |
| JANSSEN INC | 2 | 2 | ZYTIGA | Sourceable in Canada |
| MARCAN PHARMACEUTICALS INC | 2 | 2 | MAR-ABIRATERONE | Sourceable in Canada |
| PHARMARIS CANADA INC | 2 | 2 | PRZ-ABIRATERONE | Sourceable in Canada |
| PHARMASCIENCE INC | 2 | 2 | PMS-ABIRATERONE | Sourceable in Canada |
| NATCO PHARMA (CANADA) INC | 1 | 1 | NAT-ABIRATERONE | Sourceable in Canada |
| TEVA CANADA LIMITED | 2 | 0 | TEVA-ABIRATERONE | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 250 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | High-density polyethylene bottles with polypropylene caps. 500 mg: 60 tablets; 250 mg: 120 tablets. |
| Storage | Not explicitly detailed in the provided text snippet (section 11 mentioned in TOC but content not in excerpt). |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Abiraterone |
|---|---|
| ATC code | L02BX03 |
| AHFS class | 10:00.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02371065 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2371065 |
| Brand name | ZYTIGA |
| Generic / active ingredient | ABIRATERONE ACETATE : 250 MG |
| Market authorization holder | JANSSEN INC |
| Health Canada schedule | Prescription |
| ATC code | L02BX03 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L02BX |
| Current status | MARKETED |
| Status date | 28-Jul-2011 |
| Original market date | 2011-07-28 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
1 g (two 500 mg or four 250 mg tablets) once daily on an empty stomach. Taken with prednisone (5 mg or 10 mg daily depending on indication). Swallow whole with water.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to the drug or any ingredient; women who are or may potentially be pregnant.
Warnings and precautions
Mineralocorticoid excess (hypertension, hypokalemia, fluid retention); Hepatotoxicity (fatal cases reported); Cardiovascular disease caution; Skeletal muscle effects (myopathy/rhabdomyolysis).
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
17 of 24 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-ABIRATERONE FILM COATED TABLETS | 250 MG | TABLET | APOTEX INC | MARKETED | 02491397 |
| APO-ABIRATERONE FILM COATED TABLETS | 500 MG | TABLET | APOTEX INC | MARKETED | 02491400 |
| JAMP ABIRATERONE | 500 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02529629 |
| JAMP ABIRATERONE | 250 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02502305 |
| MAR-ABIRATERONE | 250 MG | TABLET | MARCAN PHARMACEUTICALS INC | MARKETED | 02503980 |
| MAR-ABIRATERONE | 500 MG | TABLET | MARCAN PHARMACEUTICALS INC | MARKETED | 02503999 |
| NAT-ABIRATERONE | 250 MG | TABLET | NATCO PHARMA (CANADA) INC | MARKETED | 02494132 |
| PMS-ABIRATERONE | 500 MG | TABLET | PHARMASCIENCE INC | MARKETED | 02501503 |
| PMS-ABIRATERONE | 250 MG | TABLET | PHARMASCIENCE INC | MARKETED | 02492601 |
| PRZ-ABIRATERONE | 250 MG | TABLET | PHARMARIS CANADA INC | MARKETED | 02540452 |
2 · Same class — other molecules in ATC L02BX
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Abiraterone | ABIRATERONE · APO-ABIRATERONE · APO-ABIRATERONE ACETATE FILM COATED TABLETS · APO-ABIRATERONE FILM COATED TABLETS · +9 more | 24 | 17 | Yes |
| Degarelix | FIRMAGON | 2 | 2 | Yes |
| Relugolix | ORGOVYX | 1 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC L02B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| L02BG | Aminogluthetimide · Anastrozole · Exemestane · Formestane · Letrozole | 79 | 39 |
| L02BB | Apalutamide · Bicalutamide · Darolutamide · Enzalutamide · Flutamide · +1 more | 46 | 11 |
| L02BA | Fulvestrant · Tamoxifen | 36 | 10 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is ZYTIGA called?
The same molecule, Abiraterone, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Abiraterone Dr.Reddy's | Latin | Australia |
| Abiraterone MedTas | Latin | Australia |
| Abiraterone Sandoz | Latin | Australia |
| ABIRATERONE VIATRIS | Latin | Australia |
| Abiraterone-Teva | Latin | Australia |
| ARX-ABIRATERONE | Latin | Australia |
| ZYRON | Latin | Australia |
| Protyga | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.